 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...919293949596979899100101...143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Elevated MIR100HG promotes colorectal cancer metastasis and is associated with poor prognosis. (Pubmed Central) - Dec 10, 2019
MIR100HG overexpression in colorectal cancer (CRC) has been demonstrated to be associated with cetuximab resistance; however, the role of MIR100HG in CRC metastasis remains unclear...In conclusion, the present study demonstrated that MIR100HG overexpression may contribute to the progression of CRC and may predict a poorer prognosis in patients with CRC. MIR100HG may therefore be considered as a novel therapeutic target and a prognostic biomarker in patients with CRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: CCR7 high expression leads to cetuximab resistance by cross-talking with EGFR pathway in PI3K/AKT signals in colorectal cancer. (Pubmed Central) - Dec 10, 2019
These findings suggested that CCR7 was a key factor in those CRC patients, who have poorer reaction to Cetuximab. So combined inhibition of CCR7 and p-AKT will represent a rational therapeutic strategy for Cetuximab resistance patients.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Effect size as a tool to identify subpopulations with improved clinical outcomes in metastatic colorectal cancer. (Level 1, West Hall - Poster Board M8) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_999;
P2
Effect size holds potential as a measure to delineate improved clinical outcomes from heterogeneous populations and could identify those trials for which further subgroup analysis should be explored. Research Funding: None
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, irinotecan / Generic mfg.
The potential in artificial intelligence-driven radiomic signature to predict survival in patients with metastatic colorectal cancer treated with cetuximab-based therapy. (Level 1, West Hall - Poster Board M3) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_995;
P3
The signature provided early prediction of sensitivity and survival and could be used to guide treatment continuation decisions. Research Funding: Merck KgaA, Other Foundation
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial. (Level 1, West Hall - Poster Board M1) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_994;
Poor PFS was seen among pts treated with cet who are RAS wt carrying polymorphisms allowing for increased binding to NK cell receptor, which in turn enhances HLAE inhibitory function of NK cell lysis. Addition of mAb against HLAE, which have been shown to restore NK cell mediated cell lysis, needs investigation in this pt population.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Genetic variants involved in bromodomain-containing protein 4 (BRD4) regulating pathway to predict outcomes in patients with metastatic colorectal cancer: Results from FIRE3 and MAVERICC trials. (Level 1, West Hall - Poster Board L10) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_981;
This finding supports a possible role of BRD4 regulating pathway in contributing to resistance to anti-VEGF/EGFR treatment. Research Funding: National Cancer Institute (grant number P30CA014089), The Gloria Borges WunderGlo Foundation-The Wunder Project, Dhont Family Foundation, San Pedro Peninsula Cancer Guild, Daniel Butler Research Fund and Call to Cure Fund
- Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE. (Level 1, West Hall - Poster Board K12) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_961;
Clinical trial information: ENCEPP/SDPP/4836. Research Funding: Sanofi
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment. (Level 1, West Hall - Poster Board K8) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_957;
P=N/A
The results of this study will offer substantial, valuable information for anti-EGFR therapeutic strategy in patients with mCRC. Research Funding: Merck Ltd., Other Government Agency
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial. (Level 1, West Hall - Poster Board J10) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_940;
Our results provide the first evidence that germline polymorphisms and tumor gene expression levels of RNF43/ZNRF3 and RSPO1 may have a predictive value in mCRC pts receiving first-line cetuximab-based treatment and contribute to modulate anti-EGFRs activity. Research Funding: National Cancer Institute grant number P30CA014089, the Gloria Borges WunderGlo Foundation-The Wunder Project, the Dhont Family Foundation, the San Pedro Peninsula Cancer Guild, the Daniel Butler Research Fund, the Call to Cure Research Fund and the Fong
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Genetic variants in immunogenic cell death (ICD) relating genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE and MAVERICC trials. (Level 1, West Hall - Poster Board J7) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_937;
But the predictive values for Cet efficacy was not evident. Research Funding: National Cancer Institute (grant number P30CA014089), The Gloria Borges WunderGlo Foundation-The Wunder Project, Dhont Family Foundation, San Pedro Peninsula Cancer Guild, Daniel Butler Research Fund and Call to Cure Fund
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
CCR5 Δ32 mutation and gene expression to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC phase III trials. (Level 1, West Hall - Poster Board H12) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_920;
Our results provide the first evidence that CCR5 Δ32 and CCR5 gene expression levels may predict outcomes in mCRC pts receiving first-line treatment with a differential effect depending on tumor location, biologic agent and chemotherapy backbone. Research Funding: National Cancer Institute grant number P30CA014089, the Gloria Borges WunderGlo Foundation-The Wunder Project, the Dhont Family Foundation, the San Pedro Peninsula Cancer Guild, the Daniel Butler Research Fund, the Call to Cure Research Fund and the Fong
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, irinotecan / Generic mfg.
RAS status in circulating-tumor DNA (ctDNA) and outcomes during rechallenge treatments with anti-EGFR antibodies in metastatic colorectal cancer (mCRC). (Level 1, West Hall - Poster Board H8) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_916;
These data can support the application of RAS monitoring into clinical practice. Clinical trial information: UMIN000015914/UMIN000015916.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
The impact of biologic agents in patients with metastatic colorectal cancer by race/ethnicity. (Level 1, West Hall - Poster Board G20) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_907;
Population-based studies are required to confirm these results. Research Funding: None
- First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC). (Level 1, West Hall - Poster Board F14) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_879;
P1/2
Clinical trial information: NCT02671435. Research Funding: AstraZeneca
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, irinotecan / Generic mfg.
Continued cetuximab in second-line treatment for patients with unresectable metastatic wild-type KRAS, NRAS, and BRAF colorectal cancer after disease progression during first-line cetuximab-based therapy. (Level 1, West Hall - Poster Board F13) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_878;
ECOG score is an independent predictor of prognosis and second-line treatment efficacy for colorectal cancer. Research Funding: Health and Family Planning Commission of Henan Province, China
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients. (Level 1, West Hall - Poster Board E22) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_865;
P1b/2
Responses were observed in two previously treated CRC pts and survival is encouraging in KRASm pts. Funded by Forty Seven and California Institute for Regenerative Medicine.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, irinotecan / Generic mfg.
Irinotecan, cetuximab, and bevacizumab (CBI) versus irinotecan, cetuximab, and placebo (CI) in irinotecan-refractory metastatic colorectal cancer (mCRC): Results from an ACCRU network randomized phase II trial. (Level 1, West Hall - Poster Board E10) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_853;
P2
Further investigation of CBI for treatment of irinotecan-refractory mCRC is warranted. Clinical trial information: NCT02292758.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, irinotecan / Generic mfg.
mFOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer: The FOCULM study. (Level 1, West Hall - Poster Board E7) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_850;
P2
Clinical trial information: NCT02063529. Research Funding: None
- Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216). (Level 1, West Hall - Poster Board E4) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_847;
P2
The noted ORR/ETS of 79.5% warrants further evaluation in a randomized trial. Clinical trial information: NCT03174405.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Effect of weight loss in patients with metastatic colorectal cancer treated within the randomized phase III FIRE-3 trial (AIO KRK 0306). (Level 1, West Hall - Poster Board D17) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_839;
Therefore, we assume that early preventative measures targeted at weight maintenance might contribute to improved outcomes among this population. Research Funding: None
- Real-world data on treatment patterns of advanced CRC in third-line and beyond. (Level 1, West Hall - Poster Board C6) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_811;
Recycling of chemotherapy and biologics in the late line setting is common and occurs more frequently than switching to a drug regimen with an alternative mechanism of action. Research Funding: NantHealth
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Overall survival of cetuximab administered every two weeks versus weekly in real-world data of U.S. patients with metastatic colorectal cancer. (Level 1, West Hall - Poster Board A17) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_780;
OS was statistically noninferior in q2w vs q1w in 1L+, and adjusted results in 1L suggest no differences between both treatment schedules. However, more data would be needed to formally test the noninferiority hypothesis in 1L.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Real-world costs of cetuximab + chemotherapy administered every two weeks versus weekly for treatment of metastatic colorectal cancer. (Level 1, West Hall - Poster Board A16) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_779;
In line with published noninferiority of overall survival with the q2w regimen, it represents an effective, cost-neutral option for treating mCRC patients. Research Funding: Merck KGaA
- ASP-1929 / Rakuten Aspyrian, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
A phase Ib study of near infrared photoimmunotherapy (NIR-PIT) using ASP-1929 in combination with nivolumab and for patients with advanced gastric or esophageal cancer (GE-PIT study, EPOC1901). (Level 1, West Hall - Poster Board L1) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_435;
Clinical trial information: JapicCTI-194969. Research Funding: Rakuten Medical, Inc
- Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216). (Level 1, West Hall - Poster Board E4) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_217;
P2
The noted ORR/ETS of 79.5% warrants further evaluation in a randomized trial. Clinical trial information: NCT03174405.
- Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). (Level 2, Ballroom) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_200;
P3
Clinical trial information: NCT02928224. Research Funding: Pfizer Inc
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial completion date, Metastases: Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design (clinicaltrials.gov) - Dec 9, 2019
P2, N=160, Recruiting, Sponsor: University of Pittsburgh
Research Funding: Pfizer Inc Trial completion date: Dec 2020 --> Dec 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial completion date, Trial primary completion date: SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN (clinicaltrials.gov) - Dec 9, 2019
P2, N=92, Active, not recruiting, Sponsor: David A. Clump, MD, PhD
Trial completion date: Dec 2020 --> Dec 2021 Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Journal: John Mendelsohn: A visionary scientist, oncologist and leader. (Pubmed Central) - Dec 8, 2019
John Mendelsohn is credited for the concept of targeting the epidermal growth factor receptor (EGFR), providing the first evidence of anticancer activity of antagonist anti-EGFR mAb, and developing the Erbitux (Cetuximab) drug for cancer patients...See related article Kumar et al. Can Res 2019; 79:4315-4323.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, Real-World Evidence: Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population. (Pubmed Central) - Dec 8, 2019
The current analysis demonstrates comparable efficacy and safety profiles of cetuximab in combination with oral and infusional FP in Chinese population. The results expand treatment options for Chinese patients and invite revision of existing treatment guidelines to incorporate oral FP-based chemotherapy plus cetuximab.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Editorial: Advances in the Systemic Therapy and Combined Modality Approaches for Head and Neck Cancer. (Pubmed Central) - Dec 8, 2019
The results expand treatment options for Chinese patients and invite revision of existing treatment guidelines to incorporate oral FP-based chemotherapy plus cetuximab. No abstract available
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: CETIDYL: Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. (clinicaltrials.gov) - Dec 5, 2019
P2, N=72, Not yet recruiting, Sponsor: GCS IHFB Cognacq-Jay
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Metastases: Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - Dec 4, 2019
P1, N=22, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
No abstract available N=16 --> 22
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Short-term outcomes and prognosis of palliative surgery for malignant bowel obstruction caused by peritoneal metastasis of colorectal cancer (Pubmed Central) - Dec 3, 2019
For patients of MBO caused by peritoneal mCRC, tumor debulking surgery may achieve higher symptom relief rate and prolong survival. Greater omental metastasis indicates poor prognosis.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Microenvironment plasticity confers cetuximab resistance. (Pubmed Central) - Dec 1, 2019
Greater omental metastasis indicates poor prognosis. No abstract available
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Molecular and IHC analysis of head and neck carcinomas associated with HPV infection. (Pubmed Central) - Dec 1, 2019
Based on the assumption that patients with HNSCC could benefit from anti-EGFR therapy (cetuximab), but the predictors are not yet defined, analyses of point mutations of ras genes (Kras, Nras) were carried out using multiplex qPCR and sequence analysis of the Braf gene...24). Keywords: head and neck carcinomas, biopsy, HPV types, PCR, p16INK4A, p53, molecular predictors, Kras, Nras, Braf.
- | cisplatin / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of veterans health affairs data. (Pubmed Central) - Nov 30, 2019
Cetuximab with RT yields inferior OS in comparison with cisplatin for the nonoperative management of stage III to IVb HNSCC. According to this study, cisplatin may be the most appropriate partner for RT in this setting.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Review, Journal: Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. (Pubmed Central) - Nov 29, 2019
Furthermore, the challenges associated with the pharmaceutical development of treatments for patients with mutant-type BRAF mCRC are ongoing. In this review, we provide an overview of the EGFR and RAS/RAF signaling pathway and antitumor activity, focusing on practical aspects such as established treatments including patient selection, treatment strategies, and future perspectives for drug development targeting the EGFR and RAS/RAF signaling pathway.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol. (Pubmed Central) - Nov 29, 2019
P=N/A
Because RAS mutations play a major role in resistance to anti-EGFR therapy for mCRC, examining evolutionary changes in these mutations during such treatment through liquid biopsy would be useful. After comprehensively analyzing the emergence of circulating RAS mutations and its clinical relevance in this study, our results should provide practical guidance on anti-EGFR therapy for mCRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Local and regional treatment response by FDG-PET-CT-scans 4 weeks after concurrent hypofractionated chemoradiotherapy in locally advanced NSCLC. (Pubmed Central) - Nov 29, 2019
Early post-treatment PET-metrics are associated with treatment outcome in LA-NSCLC patients treated with chemoradiotherapy. Both volumetric and intensity PET-metrics are useful, but more for the primary tumor than for lymph nodes.
- || cisplatin / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Journal: Final Results of a Multi-institutional Phase II Trial of Re-Irradiation with Concurrent Weekly Cisplatin and Cetuximab for Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck. (Pubmed Central) - Nov 28, 2019
P2
Younger patients had significantly improved OS. NCT00833261.
- || doxycycline / Generic Mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Journal: EVITA - A double-blind, vehicle controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. (Pubmed Central) - Nov 28, 2019
The primary endpoint of decreasing grade ≥ 2 skin rash was not met. However, using vitamin K1 cream as part of prophylactic treatment decreased the severity of acne-like skin rash according to WoMo, an alternative and more thorough skin toxicity scoring tool.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, paclitaxel / Generic Mfg.
Clinical, P2 data, Journal: Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). (Pubmed Central) - Nov 28, 2019
Further studies are needed to compare PCE with PFE in this population. UMIN000010507.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Successful desensitization of a patient with cetuximab hypersensitivity: A case report. (Pubmed Central) - Nov 28, 2019
This study reports a severe hypersensitivity reaction to cetuximab in an adult patient with colorectal cancer. This patient was successfully managed with a new safe and rapid desensitization protocol.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Immune effector functions of human IgG2 antibodies against EGFR. (Pubmed Central) - Nov 28, 2019
Together, these results demonstrate that human IgG2 antibodies against EGFR can promote significant Fc mediated effector functions, which may contribute to their clinical efficacy. The future challenge will be to identify clinical situations in which myeloid effector cells can optimally contribute to antibody efficacy.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Retrospective data, Journal: Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: A post hoc analysis of the EVITA trial. (Pubmed Central) - Nov 28, 2019
The future challenge will be to identify clinical situations in which myeloid effector cells can optimally contribute to antibody efficacy. No abstract available
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. (Pubmed Central) - Nov 28, 2019
P2
Both early response and 24 months LFS compare very well to previous LOP trials and recommend effective treatment selection and stratification by ETSS. NCT00508664.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Trichomegaly of the eyelashes induced by the epidermal growth factor receptor inhibitor cetuximab in the treatment of metastatic colorectal cancer. (Pubmed Central) - Nov 27, 2019
NCT00508664. No abstract available
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Preclinical, Journal: Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. (Pubmed Central) - Nov 27, 2019
No abstract available These results suggest that combined therapy with MEK and PI3KCA inhibitors could represent a novel and effective treatment option for HER2-amplified colorectal cancer.
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Very high Copy Number EGFR amplification in advanced gastric Tm. Upfront genomic study F1 Cdx revealed 297 Copy of EGFR gene responded quickly 3XFolfox +Cetuximab in 1.line. This is exactly Precision medicine. @KlempnerSam @agrothey @GIcancerDoc @NicoleKuderer @VivekSubbiah (Twitter) - Nov 27, 2019